A phase I trial to evaluate the safety, tolerability and pharmacokinetics of RBM-007 administered subcutaneously in healthy volunteers
Latest Information Update: 16 Dec 2021
Price :
$35 *
At a glance
- Drugs Umedaptanib pegol (Primary)
- Indications Achondroplasia
- Focus Adverse reactions; Pharmacokinetics
- 16 Dec 2021 New source identified and integrated (Japan Pharmaceutical Information Center - Clinical Trials Information record: JapicCTI205345).
- 15 Nov 2021 according to a Ribomic media release, the blood concentration of RBM-007 measured in this study provided basic pharmacokinetic data necessary for the next early Phase 2 trial, which the company is currently discussing with the Pharmaceuticals and Medical Devices Agency (PMDA).
- 15 Nov 2021 Status changed from recruiting to completed, according to a Ribomic media release.